Log in

Amicus Therapeutics Stock Price, News & Analysis (NASDAQ:FOLD)

$7.94
+0.08 (+1.02 %)
(As of 10/15/2019 07:18 AM ET)
Today's Range
$7.80
Now: $7.94
$8.17
50-Day Range
$7.47
MA: $8.98
$10.19
52-Week Range
$7.11
Now: $7.94
$14.61
Volume2.11 million shs
Average Volume4.88 million shs
Market Capitalization$2.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$91.25 million
Book Value$1.81 per share

Profitability

Net Income$-348,990,000.00
Net Margins-336.41%

Miscellaneous

Employees508
Market Cap$2.02 billion
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.


Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.34). The biopharmaceutical company earned $44.13 million during the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The company's revenue was up 107.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. View Amicus Therapeutics' Earnings History.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Amicus Therapeutics.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its third quarter 2019 earnings guidance on Thursday, October, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $48-48 million, compared to the consensus revenue estimate of $45.43 million.

What price target have analysts set for FOLD?

7 Wall Street analysts have issued 1 year target prices for Amicus Therapeutics' stock. Their predictions range from $12.59 to $31.00. On average, they expect Amicus Therapeutics' stock price to reach $18.93 in the next year. This suggests a possible upside of 138.4% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.

What is the consensus analysts' recommendation for Amicus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.

What are Wall Street analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our current 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. Galafold and AT- GAA at 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3." (8/1/2019)
  • 2. According to Zacks Investment Research, "2018 was a great year for Amicus as it received U.S. approval for its only marketed drug Galafold. The company expanded its pipeline to include 14 new gene-therapy programs for rare metabolic diseases. The company is on track to achieve its 2019 key priorities, including the global Fabry launch, Pompe late-stage development program, and development of the gene-therapy pipeline. With a very successful, now global, commercial precision medicine product in Fabry disease, a late-stage program with Breakthrough Therapy designation in late onset Pompe disease and 14 gene therapy programs for rare diseases in development, the company is strongly positioned to achieve its vision. However, it depends heavily on Galafold sales, which is a concern. Shares of the company have underperformed the industry in the past year." (5/3/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate Amicus Therapeutics Overweight. Amicus focuses on treatments for lysosomal storage disorders and rare diseases. We foresee Galafold as becoming the standard of care for Fabry disease patients with amenable mutations around the world. We think beyond this approval, Amicus has a robust pipeline." (2/26/2019)

Has Amicus Therapeutics been receiving favorable news coverage?

Media coverage about FOLD stock has been trending very negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amicus Therapeutics earned a coverage optimism score of -3.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Amicus Therapeutics.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 31,370,000 shares, an increase of 5.3% from the August 30th total of 29,800,000 shares. Based on an average trading volume of 3,930,000 shares, the short-interest ratio is currently 8.0 days. Currently, 12.7% of the company's stock are sold short. View Amicus Therapeutics' Current Options Chain.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Cara Therapeutics (CARA), Gilead Sciences (GILD), Celgene (CELG) and Inovio Pharmaceuticals (INO).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:
  • Mr. John F. Crowley, Chairman & CEO (Age 52)
  • Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
  • Dr. Jay A. Barth, Chief Medical Officer (Age 55)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $7.94.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.02 billion and generates $91.25 million in revenue each year. The biopharmaceutical company earns $-348,990,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.View Additional Information About Amicus Therapeutics.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is http://www.amicusrx.com/.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  713
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel